RT Journal Article SR Electronic T1 Role of bronchoscopy in lung cancer translational research: Tumor harvest for the lung cancer mutation consortium (LCMC) studies JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP p3817 VO 38 IS Suppl 55 A1 Rex Yung A1 Marian Rutledge A1 Peter Illei A1 Malcolm Brock A1 Charles Rudin YR 2011 UL http://erj.ersjournals.com/content/38/Suppl_55/p3817.abstract AB Introduction: The LCMC is a multi-institution collaboration to collect 1,000 cases of advanced (stage IIIB/IV) Adenocarcinoma for rapid analysis of multiple genes felt important in LC pathogenesis, to accelerate biomarker validation & discovery, to develop novel therapeutics.Aim: To address the need to harvest sufficient tumor from subjects who are often not suitable surgical candidates. To advance bronchoscopic harvest of tumor sufficient for multigene studies.Method: 68 lung AdenocarCA pts consented (3-10 and 2-11) for sending tumor tissue to Univ Colorado for multiple molecular analysis – FISH analysis for MET gene & ALK protein fusion, gene mutations by SNaPshot testing: APC, AKT1, BRAF,CTNNB1, EGFR, FLT3, JAK2, KIT, KRAS, MAP2K1, NOTCH1, NRAS, PIK3CA, PTEN, TP53. One pathologist (P.I.) review slides for tumor cellularity and adequacy for 20 extra slides.Results: 2 subjects ineligible (non AC, withdrew), 15 QNS, 33 with tissue successfully sent, 18 awaiting review of slides. Material deemed insufficient - 4 effusion cell block, 2 excised nodes, 9 bronch samples but 3/9 had sufficient tissue for in-house testing KRAS,EGFR,ALK, hence likely exhausted.Of 33 successful send-out: 17 lung surgery, 5 brain mets, 2 pleural met biopsies, 2 CT core bx. 7/33 (21%) from bronchs: 3 endo & 2 each transbronchial forceps and TBNA.Conclusion: Of 16 bronch specimens evaluated for multiplex tumor pathway testing after local site clinical testing, 7 (44%) adequate, 6 (37%) QNS, 3 (19%) likely used up for local biomarker testing. With additional effort at tumor collection at time of diagnosis, large panel testing for tumor biomarkers should be possible in a majority of cases.